Roger Pomerantz
CIK 1614936 · Chief Executive Officer · last filed 2025-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MCRB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CHALFONT, PA 18914
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INDP | Director | — | $3.34 | — | $0 | 6 | 2025-06-11 |
| Viracta Therapeutics, Inc. (VIRX) Delisted | Director | 126,478 | $0.01 | $1.2K | $0 | 19 | 2024-11-27 |
| CONTRAFECT Corp (CFRX) Delisted | Chief Executive Officer | 1 | $0.05 | $0 | $992 | 7 | 2022-02-17 |
| Intec Pharma Ltd. (NTEC) Delisted | Director | — | $9.63 | — | $0 | 2 | 2020-07-17 |
| MCRB | President and CEO | 10,699 | $1.98 | $21.2K | -$19.58M | 27 | 2019-06-14 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | 100 | $0.08 | $8 | $2.3K | 2 | 2018-07-23 |
| CONTRAFECT Corp (CFRX.W) Delisted | Director | — | — | — | $0 | 1 | 2016-05-11 |
| CONTRAFECT Corp (CFRX.Z) Delisted | Director | — | — | — | $0 | 3 | 2015-05-06 |
Recent Filings · Page 4 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-14 | MCRB | Grant (A) | — | $0 | EDGAR |
| 2019-04-04 | CONTRAFECT Corp (CFRX) Delisted | — | — | $0 | EDGAR |
| 2018-09-11 | MCRB | Sell (S) | −1,810 | -$16.3K | EDGAR |
| 2018-09-06 | MCRB | Sell (S) | −12,518 | -$113.9K | EDGAR |
| 2018-07-23 | Rubius Therapeutics, Inc. (RUBY) Delisted | Buy (P) | +100 | $2.3K | EDGAR |
| 2018-07-18 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-12 | MCRB | Mixed | — | -$8.4K | EDGAR |
| 2018-07-10 | MCRB | Mixed | — | -$272.1K | EDGAR |
| 2018-06-29 | MCRB | Mixed | — | -$219.8K | EDGAR |
| 2018-06-27 | MCRB | Mixed | −10,464 | -$556.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.